Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype

References

• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob -J-J, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–11. doi:10.1056/NEJMoa1910836
   PubMed Web of Science ®Google Scholar
• Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–47. doi:10.1200/JCO.2016.69.1584
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, Krainer M, Houede N, Santos R, Mahammedi H, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712. doi:10.1016/S1470-2045(14)70189-5
   PubMed Web of Science ®Google Scholar
• Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, et al. Final analysis of the ipilimumab versus placebo following radiotherapy phase iii trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur Urol. 2020;78(6):822–830. doi:10.1016/j.eururo.2020.07.032
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38(5):395–405. doi:10.1200/JCO.19.01638
   PubMed Web of Science ®Google Scholar
• Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, et al. Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). J Clin Oncol. 2019;37:142. doi:10.1200/jco.2019.37.7_suppl.142
   Google Scholar
• Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202–206. doi:10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353–1365. doi:10.1016/S1470-2045(20)30445-9
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, Geva R, Gottfried M, Penel N, Hansen AR, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10. doi:10.1200/JCO.19.02105
   PubMed Web of Science ®Google Scholar
• Nguyen L, Martens WM, Van Hoeck J, Cuppen AE. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11:1–12. doi:10.1038/s41467-020-19406-4
   PubMed Web of Science ®Google Scholar
• Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31:1748–1757. doi:10.1200/JCO.2012.43.1882
   PubMed Web of Science ®Google Scholar
• Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, Flynn JR, Heller G, Danila DC, Rathkopf D, et al. Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations. JCO Precis Oncol. 2020;4:355–366. doi:10.1200/po.19.00346
   PubMed Web of Science ®Google Scholar
• Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O’Connor EP, Herbert ZT, et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017;123:3532–3539. doi:10.1002/cncr.30808
   PubMed Web of Science ®Google Scholar
• van der Doelen MJ, Isaacsson Velho P, Slootbeek PHJ, Pamidimarri Naga S, Bormann M, van Helvert S, Kroeze LI, van Oort IM, Gerritsen WR, Antonarakis ES, et al. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. Eur J Cancer. 2020;136:16–24. doi:10.1016/J.EJCA.2020.05.001
   PubMed Web of Science ®Google Scholar
• van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, et al. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat Commun. 2019;10:1–13. doi:10.1038/s41467-019-13084-7
   PubMed Web of Science ®Google Scholar
• Reisländer T, Lombardi EP, Groelly FJ, Koch M, Perfetto L, Shrivastava A, Ochoa D, Wagih O, Piñero J, Kotlyar M, et al. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat Commun. 2019;10:10. doi:10.1038/s41467-019-11048-5
   PubMed Web of Science ®Google Scholar
• Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkmate 650 trial. Cancer Cell. 2020;38:489–499.e3. doi:10.1016/j.ccell.2020.08.007
   PubMed Web of Science ®Google Scholar
• Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget. 2018;9:28561–28571. doi:10.18632/oncotarget.25564
   PubMedGoogle Scholar
• Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018;128:4441–4453. doi:10.1172/JCI121924
   PubMed Web of Science ®Google Scholar
• Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, et al. MSH2 loss in primary prostate cancer. Clin Cancer Res. 2017;23:6863–6874. doi:10.1158/1078-0432.CCR-17-0955
   PubMed Web of Science ®Google Scholar
• Simnica D, Smits M, Willscher E, Fanchi LF, Kloots ISH, van Oort I, Gerritsen W, Mehra N, Binder M. Responsiveness to immune checkpoint inhibitors is associated with a peripheral blood t-cell signature in metastatic castration-resistant prostate cancer. JCO Precis Oncol. 2020:1374–1385. doi:10.1200/PO.20.00209
   PubMedGoogle Scholar
• van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N. Homologous Recombination repair deficiency and implications for tumor immunogenicity. Cancers. 2021;13:2249. doi:10.3390/cancers13092249
   PubMed Web of Science ®Google Scholar
• Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, et al. The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunol Immunother. 2019;68:1621–1633. doi:10.1007/s00262-019-02393-x
   PubMed Web of Science ®Google Scholar
• Kaur HB, Vidotto T, Mendes AA, Salles DC, Isaacs WB, Antonarakis ES, Lotan TL. Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer. Cancer Immunol Immunother. 2021;2021:1–9. doi:10.1007/S00262-021-03050-Y
   Google Scholar
• Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the association for molecular pathology. Genet Med. 2015;17:405–424. doi:10.1038/GIM.2015.30
   PubMed Web of Science ®Google Scholar
• Li M, Datto M, Duncavage E, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19:4–23. doi:10.1016/J.JMOLDX.2016.10.002
   PubMed Web of Science ®Google Scholar
• Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B, Clarke M, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest. 2020;130:1743–1751. doi:10.1172/JCI132031
   PubMed Web of Science ®Google Scholar
• Schweizer M, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, Konnick EQ, Nelson PS, Pritchard CC, Montgomery B, et al. Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA. JAMA Oncol. 2021;7(9):1378. doi:10.1001/JAMAONCOL.2021.2350
   Web of Science ®Google Scholar
• Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, Duyvesteyn K, Haidari S, van Hoeck A, Onstenk W, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575(7781):210–216. doi:10.1038/s41586-019-1689-y
   PubMed Web of Science ®Google Scholar
• Gorris MAJ, Halilovic A, Rabold K, van Duffelen A, Wickramasinghe IN, Verweij D, Wortel IM, Textor JC, de Vries IJ, Figdor CG. Eight-color multiplex immunohistochemistry for simultaneous detection of multiple immune checkpoint molecules within the tumor microenvironment. J Immunol. 2017;ji1701262. doi:10.4049/jimmunol.1701262
   Web of Science ®Google Scholar
• Sultan S, Gorris MAJ, van der Woude LL, Buytenhuijs F, Martynova E, van Wilpe S, Verrijp K, Figdor CG, de Vries IJ, Textor J. A segmentation-free machine learning architecture for immune landscape phenotyping in solid tumors by multichannel imaging. BioRxiv. 2021. doi:10.1101/2021.10.22.464548
   Google Scholar
• Calagua C, Russo J, Sun Y, Schaefer R, Lis R, Zhang Z, Mahoney K, Bubley GJ, Loda M, Taplin M-E, et al. Expression of PD-L1 in hormone-naïve and treated prostate cancer patients receiving neoadjuvant Abiraterone acetate plus prednisone and leuprolide. Clin Cancer Res. 2017;23(22):6812–6822. doi:10.1158/1078-0432.CCR-17-0807
   PubMed Web of Science ®Google Scholar
• Sharma M, Yang Z, Miyamoto H, Lucarelli G. Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer. Med. 2019:98. doi:10.1097/MD.0000000000017257
   Web of Science ®Google Scholar
• Fankhauser CD, Schüffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, Hermanns T, Poyet C, Sulser T, Moch H, et al. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget. 2018;9(12):10284–10293. doi:10.18632/oncotarget.22888
   PubMedGoogle Scholar
• Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, et al. Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer. Am J Pathol. 2018;188(6):1478–1485. doi:10.1016/j.ajpath.2018.02.014
   PubMed Web of Science ®Google Scholar
• Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, Chudakov DM. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12(5):380–381. doi:10.1038/nmeth.3364.
   PubMed Web of Science ®Google Scholar
• Simnica D, Akyüz N, Schliffke S, Mohme MV, Wenserski L, Mährle T, Fanchi LF, Lamszus K, Binder M. T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors. Oncoimmunology. 2019;8. doi:10.1080/2162402X.2019.1644110
   Web of Science ®Google Scholar
• Nazarov VI, Pogorelyy MV, Komech EA, Zvyagin IV, Bolotin DA, Shugay M, Chudakov DM, Lebedev YB, Mamedov IZ. tcR: an R package for T cell receptor repertoire advanced data analysis. BMC Bioinforma. 2015;16:1–5. doi:10.1186/S12859-015-0613-1
   PubMed Web of Science ®Google Scholar
• Huang H, Wang C, Rubelt F, Scriba TJ, Davis MM. Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening. Nat Biotechnol. 2020;38:1194–1202. doi:10.1038/s41587-020-0505-4
   PubMed Web of Science ®Google Scholar
• Sethna Z, Elhanati Y, Callan CG, Walczak AM, Mora T, Berger B. OLGA: fast computation of generation probabilities of B- and T-cell receptor amino acid sequences and motifs. Bioinformatics. 2019;35:2974–2981. doi:10.1093/BIOINFORMATICS/BTZ035
   PubMed Web of Science ®Google Scholar
• Elhanati Y, Sethna Z, Callan CG, Mora T, Walczak AM. Predicting the spectrum of TCR repertoire sharing with a data-driven model of recombination. Immunol Rev. 2018;284:167–179. doi:10.1111/IMR.12665
   PubMed Web of Science ®Google Scholar
• Chu ND, Bi HS, Emerson RO, Sherwood AM, Birnbaum ME, Robins HS, Alm EJ. Longitudinal immunosequencing in healthy people reveals persistent T cell receptors rich in highly public receptors. BMC Immunol. 2019;20:1–12. doi:10.1186/s12865-019-0300-5
   PubMed Web of Science ®Google Scholar
• Sheikh N, Cham J, Zhang L, DeVries T, Letarte S, Pufnock J, Hamm D, Trager J, Fong L. Clonotypic diversification of intratumoral T cells following sipuleucel-T treatment in prostate cancer subjects. Cancer Res. 2016;76(13):3711–3718. doi:10.1158/0008-5472.CAN-15-3173.
   PubMed Web of Science ®Google Scholar
• Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, Fong L. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014;6:238ra70. doi:10.1126/scitranslmed.3008211
   PubMed Web of Science ®Google Scholar
• Roudko V, Bozkus C, Orfanelli T, McClain CB, Carr C, O’Donnell T, Chakraborty L, Samstein R, Huang K-L, Blank SV, et al. Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell. 2020;183:1634–1649.e17. doi:10.1016/J.CELL.2020.11.004
   PubMed Web of Science ®Google Scholar
• Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, Vázquez Limón JC, Sánchez López HM, Armstrong AJ, Horvath L, et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer. 2022;160:61–71. doi:10.1016/J.EJCA.2021.09.043
   PubMed Web of Science ®Google Scholar
• Obradovic AZ, Dallos MC, Zahurak ML, Partin AW, Schaeffer EM, Ross AE, Allaf ME, Nirschl TR, Liu D, Chapman CG, et al. T-cell infiltration and adaptive treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer. Clin Cancer Res. 2020;26:3182–3192. doi:10.1158/1078-0432.CCR-19-3372
   PubMed Web of Science ®Google Scholar
• Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM, Wysocki PJ, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28:144–153. doi:10.1038/s41591-021-01600-6
   PubMed Web of Science ®Google Scholar